1887

n Cardiovascular Journal of South Africa - Diovan has EU approval for the treatment of heart attack survivors : drug trends in cardiology

USD

 

Abstract

Extracted from text ... Novartis announced recently that it has successfully completed the EU Mutual Recognition Procedure (MRP) in 14 countries for Diovan(r) (valsartan) for the treatment of heart attack survivors. Valsartan, a proven, powerful antihypertensive agent, is now indicated as a potentially life-saving therapy for the more than 750 000 people in the EU who are at risk of a recurrent heart attack or other serious outcome such as cardiovascular mortality, hospitalisation for heart failure, resuscitated cardiac arrest or stroke. EU regulatory authorities are also evaluating valsartan for people with heart failure. 'The most widely prescribed ARB globally, valsartan provides a unique range of ..

Loading

Article metrics loading...

/content/cardio/16/3/EJC23995
2005-05-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error